Understanding Secondary Malignancies in CAR-T Therapy

This chapter explores the risks of developing secondary malignancies after CAR-T cell therapy, discussing findings from studies on lymphoma patients and FDA reports on T-cell lymphomas associated with CAR-T products. The speakers analyze the challenges of attributing T-cell lymphomas to CAR-T therapy, methods to differentiate between different forms of lymphomas, and the implications of using CAR-T earlier in the treatment course. Despite the real risk of secondary malignancies, they express relative reassurance due to the low observed incidence so far.